FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasis

Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.

According to a press release from the manufacturer, the approval was supported by the phase 3 ICONIC trial program, which enrolled approximately 2,500 adult, pediatric, and adolescent patients across several studies, patients with psoriasis involving high-impact sites, and head-to-head comparisons against an active comparator. In those superiority trials, about 70% of treated patients achieved an Investigator’s Global Assessment score of 0 or 1, and 55% achieved PASI 90 at week 16, according to the company. Johnson & Johnson also said adverse reaction rates were within 1.1% of placebo through week 16, with no new safety signals identified through week 52.

The approval may be notable for clinicians managing patients cycling through treatments who remain uncontrolled. Recent International Psoriasis Council guidance has sought to clarify when topical treatment failure should prompt transition to systemic treatment, including after 2 consecutive 4-week courses without adequate response.

“ICOTYDE delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once‑daily pill, making it an easy addition to a patient’s routine," said Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health, in the news release. “With new guidance from the International Psoriasis Council that clarifies when to move beyond cycling on topical treatments to systemic therapy, an innovative option like ICOTYDE is a potential game‑changer for many adult and adolescent patients.”

Source: J&J press release. March 18, 2026.